Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
HB-0034 by Huabo Biopharm (Shanghai) for Pyoderma Gangrenosum: Likelihood of Approval
HB-0034 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase I for Pyoderma Gangrenosum. According to GlobalData,...
HB-0034 by Huabo Biopharm (Shanghai) for Hidradenitis Suppurativa: Likelihood of Approval
HB-0034 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase I for Hidradenitis Suppurativa. According to GlobalData,...
HB-0034 by Huabo Biopharm (Shanghai) for Squamous Cell Carcinoma: Likelihood of Approval
HB-0034 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase I for Squamous Cell Carcinoma. According to...
HB-0034 by Huabo Biopharm (Shanghai) for Systemic Lupus Erythematosus: Likelihood of Approval
HB-0034 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase I for Systemic Lupus Erythematosus. According to...
HB-0034 by Huabo Biopharm (Shanghai) for Ulcerative Colitis: Likelihood of Approval
HB-0034 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase I for Ulcerative Colitis. According to GlobalData,...
HB-0045 by Huabo Biopharm (Shanghai) for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
HB-0045 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to...
HB-0025 by Huabo Biopharm (Shanghai) for Solid Tumor: Likelihood of Approval
HB-0025 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase I for Solid Tumor. According to GlobalData,...
HB-0045 by Huabo Biopharm (Shanghai) for Kidney Cancer (Renal Cell Cancer): Likelihood of Approval
HB-0045 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase II for Kidney Cancer (Renal Cell Cancer)....
HB-0045 by Huabo Biopharm (Shanghai) for Fallopian Tube Cancer: Likelihood of Approval
HB-0045 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase II for Fallopian Tube Cancer. According to...
HB-0045 by Huabo Biopharm (Shanghai) for Metastatic Colorectal Cancer: Likelihood of Approval
HB-0045 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase II for Metastatic Colorectal Cancer. According to...
HB-0045 by Huabo Biopharm (Shanghai) for Head And Neck Cancer: Likelihood of Approval
HB-0045 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase II for Head And Neck Cancer. According...
HB-0045 by Huabo Biopharm (Shanghai) for Metastatic Prostate Cancer: Likelihood of Approval
HB-0045 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase II for Metastatic Prostate Cancer. According to...
HB-0045 by Huabo Biopharm (Shanghai) for Peritoneal Cancer: Likelihood of Approval
HB-0045 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase II for Peritoneal Cancer. According to GlobalData,...
HB-002.1T by Huabo Biopharm (Shanghai) for Extrahepatic Bile Duct Cancer: Likelihood of Approval
HB-002.1T is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase I for Extrahepatic Bile Duct Cancer. According...
HB-0045 by Huabo Biopharm (Shanghai) for Endometrial Cancer: Likelihood of Approval
HB-0045 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase II for Endometrial Cancer. According to GlobalData,...
HB-0045 by Huabo Biopharm (Shanghai) for Sarcomas: Likelihood of Approval
HB-0045 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase II for Sarcomas. According to GlobalData, Phase...
HB-0045 by Huabo Biopharm (Shanghai) for Metastatic Lung Cancer: Likelihood of Approval
HB-0045 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase II for Metastatic Lung Cancer. According to...
HB-0045 by Huabo Biopharm (Shanghai) for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
HB-0045 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC). According...
HB-0045 by Huabo Biopharm (Shanghai) for Metastatic Breast Cancer: Likelihood of Approval
HB-0045 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase II for Metastatic Breast Cancer. According to...
HB-0045 by Huabo Biopharm (Shanghai) for Metastatic Ovarian Cancer: Likelihood of Approval
HB-0045 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase II for Metastatic Ovarian Cancer. According to...